Expectations

Every patient, in fact
every member of the methadone community, has a right to expect that
someone who represents themselves as a methadone advocate be knowledgeable
in all aspects of methadone treatment.


NAMA has created the Methadone Advocate Training and
Methadone Advocate Certification for a whole host of reasons. Most of
which we will discuss in Washington, DC at the first CMA Training..
However, the most obvious is:

To give persons interested in doing methadone advocacy work the best
possible set of tools to accomplish the goals of Methadone Advocacy.

 


CONTINUE

Similar Posts

  • News

    Admin 08/25/2022

    Congratulations to Sara Gefvert, the 2022 Lane/Holden Award Winner! November 2, 2022 The 2022 Richard Lane/Robert Holden Patient Advocacy Award was presented at an Awards Reception held in conjunction with the 2022 Conference of the American Association for the Treatment of Opioid Dependence (AATOD) in Baltimore, Maryland on November 2, 2022. Richard Lane/Robert Holden Patient…

  • Buprenorphine treats opiate addiction in office; Two Sublingual Formulations Approved

    Admin 01/17/2023

    Mechcatie, Elizabeth. Family Practice News 32(22): 7. November 15, 2002 The approval of the partial opioid agonist buprenorphine for treating opiate dependence has paved the way for office-based treatment of opioid addiction and far greater access to treatment for hundreds of thousands of heroin addicts across the country. Two sublingual formulations have been approved: Buprenorphine…

  • Lindesmith Center Seminar Schedule

    Admin 08/05/2022

    The Lindesmith Center’s SPECIAL DRUG POLICY SEMINAR SERIES Summer and Fall 1996 DRUG TREATMENT RECONSIDERED: HARM REDUCTION PERSPECTIVES The Lindesmith Center is presenting a special seminar series on the relationship between drug treatment and harm reduction. Harm reduction services focus on reducing the negative consequences of drug use among those unwilling or unable to abstain….

  • Publication Index

    Admin 03/18/2022

    FOR IMMEDIATE RELEASE: October 9, 2002 NIDA Contact: Michelle Person 301-443-6245 SAMHSA Contact: Leah Young 301-443-8956 NIDA Research and SAMHSA Physician Training Combine to Put Care for Opiate Dependence in Hands of Family Doctor. Buprenorphine, a new medication developed through more than a decade of research supported by the National Institute on Drug Abuse (NIDA),…

  • Late Breaking News

    Admin 09/01/2021

    Best Practices: Treatment of Opiate Dependence Conference Update   Physician Training for Use of Buprenorphine   The conference planning committee working with the Center for Substance Abuse Treatment and the American Academy of Addictions Psychiatry will be offering the following 8-hour physician workshop during the Best Practices: Treatment of Opiate Dependence Conference, scheduled for March…

  • Focus On

    Admin 09/16/2021

    Issues To Focus On LAAM Manufacture to Be Discontinued August 23, 2003 Washington, D.C. Roxanne the manufacturer of LAAM has informed the FDA that manufacture of the medication is being discontinued. Distribution will continue until the inventory is depleted. Roxanne estimates this to be in early January 2004. The reason for the action is the…